专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013134743A1 CONDITIONALLY ACTIVE ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：有活性的抗真菌生长因子受体抗体及其使用方法
公开(公告)号：WO2013134743A1
公开(公告)日：2013-09-12
申请号：PCT/US2013030055
申请日：2013-03-08
申请人： HALOZYME INC
发明人： WEI GE , FROST GREGORY , HUANG LEI , SHEPARD H MICHAEL , VAUGHN DANIEL EDWARD
IPC分类号： C07K16/28 , C07K16/30 , G01N33/53 , G01N33/574
CPC分类号： C07K16/2863 , A61K39/39558 , A61K47/6825 , A61K47/6849 , A61K47/6851 , A61K2039/505 , C07K16/30 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/92 , A61K39/00
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
摘要翻译：本文提供了修饰的抗EGFR抗体和编码修饰的抗EGFR抗体的核酸分子。还提供了使用修饰的抗EGFR抗体的治疗和使用的方法。

2. 发明申请

WO2013063155A3 COMPANION DIAGNOSTIC FOR ANTI-HYALURONAN AGENT THERAPY AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗血小板药物治疗的联合诊断方法及其使用方法
公开(公告)号：WO2013063155A3
公开(公告)日：2013-07-11
申请号：PCT/US2012061743
申请日：2012-10-24
申请人： HALOZYME INC
发明人： JIANG PING , SHEPARD H MICHAEL , HUANG LEI
IPC分类号： A61K38/47 , G01N33/574
CPC分类号： C12N9/2474 , A61K38/47 , A61K47/10 , C07K14/47 , C07K2319/00 , C07K2319/30 , C07K2319/735 , G01N33/566 , G01N33/574 , G01N33/57488 , G01N33/6893 , G01N2333/705 , G01N2400/40 , G01N2800/52
摘要： Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.
摘要翻译：提供了用透明质酸药物如透明质酸降解酶进行癌症治疗的受试者鉴别的方法和诊断剂。提供用于检测和定量生物样品中透明质酸的诊断剂，并用抗透明质酸药物（例如透明质酸降解酶）监测癌症治疗。还提供了用于实施方法的组合和试剂盒。

3. 发明专利

AU2013229786B2 Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof 未知
公开(公告)号：AU2013229786B2
公开(公告)日：2017-06-22
申请号：AU2013229786
申请日：2013-03-08
申请人： HALOZYME INC
发明人： WEI GE , FROST GREGORY , HUANG LEI , SHEPARD H MICHAEL , VAUGHN DANIEL EDWARD
IPC分类号： C07K16/28 , C07K16/30 , G01N33/53 , G01N33/574
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.

4. 发明专利

AU2012328880B2 Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof 未知
公开(公告)号：AU2012328880B2
公开(公告)日：2017-02-23
申请号：AU2012328880
申请日：2012-10-24
申请人： HALOZYME INC
发明人： JIANG PING , SHEPARD H MICHAEL , HUANG LEI
IPC分类号： A61K38/47 , G01N33/574
摘要： Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.

5. 发明专利

HK1213206A1 用於抗透明質酸試劑療法的搭配診斷及其使用方法未知
公开(公告)号：HK1213206A1
公开(公告)日：2016-06-30
申请号：HK16101363
申请日：2016-02-04
申请人： HALOZYME INC
发明人： JAING PING , SHEPARD HAROLD MICHAEL , HUANG LEI
IPC分类号： A61K20060101 , G01N20060101

6. 发明专利

SG11201405553YA CONDITIONALLY ACTIVE ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：SG11201405553YA
公开(公告)日：2014-11-27
申请号：SG11201405553Y
申请日：2013-03-08
申请人： HALOZYME INC
发明人： WEI GE , FROST GREGORY , HUANG LEI , SHEPARD H MICHAEL , VAUGHN DANIEL EDWARD
IPC分类号： C07K16/28 , C07K16/30 , G01N33/53 , G01N33/574

7. 发明专利

CA2810668A1 METHODS FOR ASSESSING AND IDENTIFYING OR EVOLVING CONDITIONALLY ACTIVE THERAPEUTIC PROTEINS 未知
公开(公告)号：CA2810668A1
公开(公告)日：2012-03-15
申请号：CA2810668
申请日：2011-09-08
申请人： HALOZYME INC
发明人： KODANDAPANI LALITHA , BOOKBINDER LOUIS HOWARD , FROST GREGORY IAN , SHERIDAN PHILIP LEE , SHEPARD HAROLD MICHAEL , WEI GE , HUANG LEI
IPC分类号： C07K16/30 , G01N33/53 , G01N33/574 , G01N33/68
摘要： Methods for evolving or selecting therapeutic proteins with reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.

8. 发明专利

CA2866612A1 CONDITIONALLY ACTIVE ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 未知
公开(公告)号：CA2866612A1
公开(公告)日：2013-09-12
申请号：CA2866612
申请日：2013-03-08
申请人： HALOZYME INC
发明人： WEI GE , FROST GREGORY IAN , HUANG LEI , SHEPARD H MICHAEL , VAUGHN DANIEL EDWARD
IPC分类号： C07K16/28 , C07K16/30 , G01N33/53 , G01N33/574
摘要： Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.

9. 发明专利

MX2013002679A METODOS PARA EVALUAR E IDENTIFICAR O EVOLUCIONAR PROTEINAS TERAPEUTICAS CONDICIONALMENTE ACTIVAS. 未知
公开(公告)号：MX2013002679A
公开(公告)日：2013-06-18
申请号：MX2013002679
申请日：2011-09-08
申请人： HALOZYME INC
发明人： HUANG LEI , WEI GE , GREGORY IAN FROST , KODANDAPANI LALITHA , BOOKBINDER LOUIS HOWARD , SHERIDAN PHILIP LEE , SHEPARD HAROLD MICHAEL
IPC分类号： C07K16/30 , G01N33/53 , G01N33/574 , G01N33/68
摘要： Se proporcionan métodos para evolucionar o seleccionar proteínas terapéuticas con efectos colaterales adversos reducidos y las proteínas resultantes. Por ejemplo, se proporciona en la presente un ensayo in vitro para identificar condicionalmente proteínas terapéuticas activas que exhiben mejor actividad dentro de un ambiente in vivo comparado con otro ambiente in vivo. Los métodos incluyen las etapas de a) probar la actividad de una proteína bajo condiciones en las cuales se desea actividad normal o incrementada; b) probar la actividad de la proteína bajo condiciones en las cuales se desea la actividad reducida comparada con la normal; y c) comparar la actividad en a) con b) y seleccionar/identificar una proteína que tiene mayor actividad en a) comparado con b . La proteína seleccionada/identificada es una proteína condicionalmente activa.

10. 发明专利

NZ630020A Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof 未知
公开(公告)号：NZ630020A
公开(公告)日：2016-08-26
申请号：NZ63002013
申请日：2013-03-08
申请人： HALOZYME INC
发明人： VAUGHN DANIEL EDWARD , HUANG LEI , FROST GREGORY , WEI GE , SHEPARD H MICHAEL
IPC分类号： C07K16/28 , C07K16/30 , G01N33/53 , G01N33/574
摘要： Disclosed is a modified anti-human epidermal growth factor receptor (EGFR) antibody, or antigen-binding fragment thereof, comprising the amino acid replacement Y104D in the variable heavy chain of the unmodified antibody, wherein: the modified anti-EGFR antibody or antigen-binding fragment thereof comprises a variable heavy (VH) chain and a variable light (VL) chain, or a portion thereof that is sufficient to bind EGFR antigen, whereby the VH alone or both the VH and VL is modified; the portion thereof is sufficient to form an antigen binding site and contains the amino acid replacement; the unmodified anti-EGFR antibody is selected from among: i) cetuximab, or an antigen-binding fragment thereof, comprising a variable heavy chain set forth in SEQ ID NO:3 and a variable light chain set forth in SEQ ID NO:4 or 10; ii) a variant of i) comprising a variable heavy chain having a sequence of amino acids that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:3, and a variable light chain having a sequence of amino acids that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:4 or 10, wherein the variant does not comprise the amino acid replacement and specifically binds to EGFR; and iii) a humanized form of i) or ii); the modified anti-EGFR antibody, or antigen-binding fragment thereof, exhibits a ratio of binding activity to human epidermal growth factor receptor (EGFR) or a soluble fragment thereof under conditions in a tumour environment compared to under conditions in a non-tumour environment of at least 2.0; conditions in a tumour environment comprise one or both of pH between 6.0 to 6.5 or lactate concentration between 5 mM to 20 mM, and protein concentration of 10 mg/mL to 50 mg/mL; and conditions in a non-tumour environment comprise one or both of pH of 7.4 or lactate concentration between 0.5 mM to 5 mM, and protein concentration of 10 mg/mL to 50 mg/mL, whereby the anti-EGFR antibody or fragment thereof is conditionally active under conditions in the tumour microenvironment.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式